The IZI Stem Cell Research Center, invested by the Group, houses one of the world’s first and Korea’s first teams to receive approval from the Ministry of Food and Drug Safety for anti-cancer cell therapy biopharmaceuticals. As a biotech enterprise leading the cell therapy revolution, it is rewriting treatment paradigms with disruptive technology at the frontiers of cancer treatment and regenerative medicine. With cutting-edge natural killer (NK) immune cell therapy and innovative umbilical cord gel stem cell technology as its twin pillars, it opens up entirely new possibilities for human health.

The NK cell therapy of the IZI Stem Cell Research Center has demonstrated industry-leading efficacy data in clinical trials for liver cancer and gastric cancer, while building complete regenerative medicine and premium medical aesthetics solutions. Backed by an international-standard GMP production system, it is accelerating its global market expansion so that innovative therapies can benefit a wider population.

Aiming for “No. 1 in Korea, world-class excellence”, the IZI Stem Cell Research Center continues to drive innovation in cell therapy. It believes that precisely targeted NK cell therapy will ultimately rewrite the history of humanity’s fight against cancer, redefine the boundaries of life, and define the future of cells. We look forward to joining hands with elite partners worldwide to usher in a new era of cell therapy!